CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight [Yahoo! Finance]
Nkarta, Inc. (NKTX)
Company Research
Source: Yahoo! Finance
Delhi, May 01, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: CD70 Targeting Therapies In Clinical Trials: 20 Therapies CD 70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase Insight On CD70 Targeting Therapy Technology Platforms: 6 Platforms FDA & EMA Designations Insight: Orphan, FTD, RMAT Designation Combination Stratagems for CD70 Targeting Therapies Insight On 10 Companies Involved In Development Of CD70 Therapies Download Report: https://www.kuickresearch.com/report-cd70-antibodies-cd70-antibody-targeting-therapies-cd70-targeting-therapies-market-cd70-targeting-therapies-trials-cd70-antibodies-fda-approval The cell surface protein CD70 has attracted a lot of interest in the field of oncology as a possible target for cancer treatment. Its many roles in both the regular physiological processes and development of cancer make it a desirable target for
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Needham & Company LLC from $15.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]Yahoo! Finance
NKTX
Earnings
- 5/9/24 - Miss
NKTX
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/25/24 - Form ARS
- NKTX's page on the SEC website